news
Ashwagandha market faces crisis over leaf vs. root regulation
The $1.5 billion ashwagandha market is in chaos as global regulators debate what parts of the plant can be used in supplements, exposing a major quality control gap. Without clear standards for leaf versus root, distinguishing plant parts is tough, and it threatens the entire botanical industry.
The $1.5 billion ashwagandha market is in chaos as global regulators debate what parts of the plant can be used in supplements, exposing a major quality control gap. Without clear standards for leaf versus root, distinguishing plant parts is tough, and it threatens the entire botanical industry.
The architecture take
The ashwagandha in your stress support supplement might be more leaf than root, and regulators are just now catching up. This isn't just about botanical purity; it's about efficacy for your nervous system. Root extracts are where the adaptogenic power is—think better cortisol management and a calmer HPA axis. Leaves? They've got some bioactives, but way less of what you're paying for. The industry's gotten away with vague labeling for too long, but now with big money on the line, someone's finally asking if your ashwagandha is actually doing what it promises. I just want to know if the thing I'm taking to smooth out my nervous system is actually doing anything or if I'm just flushing money. Watch for new product labels touting 'root only' or 'high-standard root extract' as brands try to differentiate.